141 related articles for article (PubMed ID: 35395440)
1. Heteroleptic Gold(I)-bisNHC complex with excellent activity in vitro, ex vivo and in vivo against endometrial cancer.
Xiao Q; Liu Y; Jiang G; Liu Y; Huang Y; Liu W; Zhang Z
Eur J Med Chem; 2022 Jun; 236():114302. PubMed ID: 35395440
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
Landini I; Massai L; Cirri D; Gamberi T; Paoli P; Messori L; Mini E; Nobili S
J Inorg Biochem; 2020 Jul; 208():111079. PubMed ID: 32497830
[TBL] [Abstract][Full Text] [Related]
3. A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis.
König P; Zhulenko R; Suparman E; Hoffmeister H; Bückreiß N; Ott I; Bendas G
Cancer Chemother Pharmacol; 2023 Jul; 92(1):57-69. PubMed ID: 37272932
[TBL] [Abstract][Full Text] [Related]
4. Halo and Pseudohalo Gold(I)-NHC Complexes Derived from 4,5-Diarylimidazoles with Excellent
Bian M; Fan R; Jiang G; Wang Y; Lu Y; Liu W
J Med Chem; 2020 Sep; 63(17):9197-9211. PubMed ID: 32787098
[TBL] [Abstract][Full Text] [Related]
5. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo.
Hopper M; Yun JF; Zhou B; Le C; Kehoe K; Le R; Hill R; Jongeward G; Debnath A; Zhang L; Miyamoto Y; Eckmann L; Land KM; Wrischnik LA
Int J Antimicrob Agents; 2016 Dec; 48(6):690-694. PubMed ID: 27839893
[TBL] [Abstract][Full Text] [Related]
6. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
7. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
8. Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase.
Bellisola G; Fracasso G; Ippoliti R; Menestrina G; Rosén A; Soldà S; Udali S; Tomazzolli R; Tridente G; Colombatti M
Biochem Pharmacol; 2004 May; 67(9):1721-31. PubMed ID: 15081871
[TBL] [Abstract][Full Text] [Related]
9. [Potential Anticancer Activity of Auranofin].
Momose I; Onodera T; Kawada M
Yakugaku Zasshi; 2021; 141(3):315-321. PubMed ID: 33642497
[TBL] [Abstract][Full Text] [Related]
10. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
11. Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis.
De Franco M; Saab M; Porchia M; Marzano C; Nolan SP; Nahra F; Van Hecke K; Gandin V
Chemistry; 2022 Dec; 28(70):e202201898. PubMed ID: 36106679
[TBL] [Abstract][Full Text] [Related]
12. Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics.
Liu Y; Lu Y; Xu Z; Ma X; Chen X; Liu W
Drug Discov Today; 2022 Jul; 27(7):1961-1973. PubMed ID: 35192926
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c.
Rigobello MP; Scutari G; Folda A; Bindoli A
Biochem Pharmacol; 2004 Feb; 67(4):689-96. PubMed ID: 14757168
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.
Sze JH; Raninga PV; Nakamura K; Casey M; Khanna KK; Berners-Price SJ; Di Trapani G; Tonissen KF
Redox Biol; 2020 Jan; 28():101310. PubMed ID: 31514052
[TBL] [Abstract][Full Text] [Related]
15. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.
Schuh E; Pflüger C; Citta A; Folda A; Rigobello MP; Bindoli A; Casini A; Mohr F
J Med Chem; 2012 Jun; 55(11):5518-28. PubMed ID: 22621714
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
17. Effect of metal complexes on thioredoxin reductase and the regulation of mitochondrial permeability conditions.
Bragadin M; Scutari G; Folda A; Bindoli A; Rigobello MP
Ann N Y Acad Sci; 2004 Dec; 1030():348-54. PubMed ID: 15659816
[TBL] [Abstract][Full Text] [Related]
18. Gold Nanoclusters as Nanoantibiotic Auranofin Analogues.
Ndugire W; Raviranga NGH; Lao J; Ramström O; Yan M
Adv Healthc Mater; 2022 May; 11(9):e2101032. PubMed ID: 34350709
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.
Liu JJ; Liu Q; Wei HL; Yi J; Zhao HS; Gao LP
Pharmazie; 2011 Jun; 66(6):440-4. PubMed ID: 21699084
[TBL] [Abstract][Full Text] [Related]
20. Expression of the thioredoxin system in an in vivo-like cancer cell environment upon auranofin treatment.
Bhatia M; Lovitt CJ; Raninga PV; Avery VM; Di Trapani G; Tonissen KF
Eur J Cell Biol; 2016 Oct; 95(10):378-388. PubMed ID: 27567536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
